Longitudinal Serum Ferritin Cut-Off Level for Cardiac Iron Overload Prediction in Transfusion-Dependent Thalassemia in a Resource Limited Country

Supachai Ekwattanakit(Siriraj Hospital), Vip Viprakasit(Siriraj Hospital), Boonying Rerkudom(Siriraj Hospital), John C. Wood(Children's Hospital of Los Angeles), Kleebsabai Sanpakit, Pairash Saiviroonporn(Siriraj Hospital), Rungroj Krittayaphong(Siriraj Hospital), Jassada Buaboonnam, Noppadol Siritanaratkul(Siriraj Hospital), Archrob Khuhapinant(Siriraj Hospital), Stephan G. Erberich(University of Southern California)
Blood
December 2, 2016
10.1182/blood.v128.22.1282.1282
Cited by 0

Related Papers

Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial
|The Lancet|2015|518
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
Clinical Classification, Screening and Diagnosis for Thalassemia
|Hematology/Oncology Clinics of North America|2018|262
Crenolanib is active against models of drug-resistant FLT3-ITD−positive acute myeloid leukemia
|Blood|2013|184
Infection-related complications during treatment for childhood acute lymphoblastic leukemia
|Annals of Oncology|2016|176